GovBidAlerts
← My Opportunities
Grantopen🌐 United StatesPAR-25-226

Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)

National Institutes of Health

Details

Posted
Nov 22, 2024
Response deadline
Nov 19, 2026, 12:00 AM UTC (130d)
Type
Grant
Category
93.242
Status
open
Buyer
National Institutes of Health
Department
HHS-NIH11
Jurisdiction
United States
Reference #
PAR-25-226
Doc Type
synopsis
Opp Status
posted
Finding similar opportunities…

This listing is a summary from United States's open procurement data. We ingest every field the feed publishes; the full solicitation documents are on the source portal.